Application
Immunofluorescence staining of methanol-fixed Hela cells using eIF4G Antibody .Application
Western blot analysis of extracts from HepG2 and HT29 cells using eIF4G Antibody .Application
Western blot analysis of extracts from HepG2 and HT29 cells using eIF4G (Ab-1232) AntibodyApplication
Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using eIF4G Antibody (left) or the same antibody preincubated with blocking peptide (right).| Product Name | eIF4G antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to eIF4GeIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis |
| Immunogen | Peptide sequence around aa.1230~1234 (P-V-S-P-L) derived from Human eIF4G. |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | ICC/IFIHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100, ICC/IF: 1:100~1:200. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | DKFZp686A1451 EIF-4G1 EIF4F EIF4G EIF4GI P220 EIF4G1 eucaryotic translation initiation factor 4G EIF4-gamma eukaryotic translation initiation factor 4 gamma 1 eIF-4-gamma 1 eukaryotic translation initiation factor 4 gamma 1 |
|---|---|
| Target | eIF4G |
| Molecular Weight(MW) | 220 (note) |
Application
Immunofluorescence staining of methanol-fixed Hela cells using eIF4G Antibody .
Application
Western blot analysis of extracts from HepG2 and HT29 cells using eIF4G Antibody .
Application
Western blot analysis of extracts from HepG2 and HT29 cells using eIF4G (Ab-1232) Antibody
Application
Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using eIF4G Antibody (left) or the same antibody preincubated with blocking peptide (right).| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100, ICC/IF: 1:100~1:200. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
